Masimo CEO 'Wholeheartedly' Feels Apple Watch Users Are Better Off Without Blood Oxygen Monitoring Feature
Portfolio Pulse from Rounak Jain
Masimo Corp. CEO Joe Kiani criticized Apple Inc. for offering a blood oxygen monitoring feature on its Apple Watch Series 9 and Apple Watch Ultra 2, which he deems unreliable due to infrequent readings and lack of FDA approval for medical use. Apple has disabled the feature to avoid an import ban in the U.S., and the watches are back on sale. Masimo seeks $3 per watch sold in a patent dispute, while Apple alleges Masimo's W1 watch violates its design patents.
January 19, 2024 | 6:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Masimo's CEO criticized Apple's blood oxygen feature, which could highlight Masimo's own technology and potentially benefit its reputation and sales.
The CEO's comments could be seen as a competitive positioning strategy, emphasizing Masimo's own products' reliability over Apple's. This could positively impact Masimo's stock in the short term as investors may perceive the company as a better alternative in medical monitoring technology.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Apple disabled the blood oxygen monitoring feature on its latest watches due to a patent dispute, which may affect consumer perception and sales of the Apple Watch Series 9 and Apple Watch Ultra 2.
The removal of the blood oxygen monitoring feature could be seen as a negative by consumers who value this health-related functionality, potentially leading to decreased demand for the latest Apple Watch models. This could negatively impact Apple's stock in the short term as the market reacts to the product change and ongoing legal issues.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90